Dr. Elena Marchetti | Gastroenterologist, Digestive Health Specialist | Nova Digestive Expert Series
The peppermint-caraway clinical data is among the most consistent in functional gastroenterology. What Nova adds is the delivery system. Sublingual oil absorption bypasses the breakdown stage that makes most oral supplements unpredictable in their concentration.
On the Clinical Evidence
In over fifteen years of clinical practice in gastroenterology, I have seen patients cycle through the full range of available interventions for functional digestive complaints, including post-meal gas pressure, chronic bloating, and upper gastrointestinal discomfort, without finding lasting relief. The majority of pharmaceutical options for functional dyspepsia are limited, and the evidence base for many supplement interventions is thin at best.
The peppermint and caraway oil combination is a notable exception. The clinical literature on this combination is, by the standards of functional gastroenterology, genuinely consistent. The 2019 systematic review and meta-analysis by Li and colleagues, which pooled five randomised controlled trials across 578 patients, demonstrated statistically significant global symptom improvement with a Number Needed to Treat of 3. An NNT of 3 is a clinically meaningful result. For context, many pharmaceutical agents used in functional gastrointestinal disorders have NNTs of 5 to 15 or higher. An NNT of 3 means that for every three patients treated, one experiences meaningful improvement directly attributable to the intervention rather than placebo effect.
The Madisch 1999 randomised controlled equivalence trial added a particularly important data point: the peppermint-caraway combination was shown to be therapeutically equivalent to cisapride, a prokinetic pharmaceutical that was, at the time, a standard clinical treatment for functional dyspepsia. The botanical combination matched the drug's performance across four weeks of treatment, with a comparable safety profile.
On the Delivery System
What I find clinically significant about the Elysian formulation is not the ingredients themselves, which are well-documented, but the delivery format. This distinction is not cosmetic. It has direct pharmacokinetic implications for whether the active compounds reach a therapeutically relevant concentration.
Standard oral capsules containing botanical compounds are subject to first-pass hepatic metabolism. When a compound is swallowed, it is absorbed through the intestinal wall, enters the portal circulation, and passes through the liver before reaching systemic circulation. The liver metabolises a portion of the compound, reducing the bioavailable dose. For many lipophilic botanical compounds, this reduction is significant.
Sublingual oil administration bypasses this process entirely. Compounds absorbed through the sublingual mucosa enter the capillary network directly, reaching systemic circulation without hepatic first-pass processing. Published bioavailability comparisons have documented that sublingual delivery produces substantially higher systemic concentrations for compounds that undergo significant first-pass metabolism, in some cases more than double the bioavailable dose from the equivalent oral amount.
For a botanical formula where the active compounds are lipophilic essential oils, this distinction matters clinically. It is the difference between a predictable, consistent systemic concentration and an unpredictable one that varies with gastric conditions, capsule dissolution, intestinal transit, and individual hepatic metabolism.
Clinical Relevance for Functional Digestive Patients
The patients I see with chronic functional digestive complaints have typically tried multiple interventions before arriving at my practice. Probiotics. Enzyme capsules. Antacids. Various herbal preparations. The consistent failure pattern is that these interventions are reactive and inconsistent, taken when symptoms are already present, delivering unpredictable concentrations of active compounds, and addressing symptoms rather than the underlying motility pattern.
A daily sublingual botanical protocol addresses several of these failure points simultaneously. It provides consistent daily dosing before the motility pattern produces symptoms. It delivers active compounds in a format that bypasses the pharmacokinetic variability of oral capsules. And the botanical compounds themselves, particularly the peppermint-caraway combination, have a documented mechanism of action on gastrointestinal smooth muscle tone that is relevant to the functional patterns most commonly presenting in clinical practice.
I do not recommend botanical supplements as replacements for medical evaluation. Patients with chronic digestive symptoms should be properly assessed to rule out structural pathology. But for patients with confirmed functional digestive disorders where conventional pharmaceutical options have been limited or unsuccessful, the evidence base for a well-formulated daily carminative botanical protocol is, in my view, clinically credible.
References
- Li J, et al. A Combination of Peppermint Oil and Caraway Oil for the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2019. PMC6885176.
- Madisch A, et al. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination as compared to cisapride. Arzneimittelforschung. 1999;49(11):925-32. PMID: 10604046.
- StatPearls. Drug Bioavailability. National Institutes of Health Bookshelf. ncbi.nlm.nih.gov/books/NBK557852
